Core Insights - The core viewpoint of the article is that the Schwyz Group has reported strong financial performance for the fiscal year 2024-2025, exceeding revenue targets significantly, driven by robust growth in its oncology segment and stable performance in cardiovascular metabolism [1] Financial Performance - The group achieved a revenue of €6.9 billion, representing a year-on-year increase of 16.2%, surpassing the annual target of €6 billion [1] - The oncology business emerged as the main growth driver, generating sales of €2.21 billion, which is a 54.6% increase compared to the previous year, and accounted for 32.2% of total revenue [1] Business Segments - The growth in the oncology segment was primarily fueled by the launch of the targeted drug Voranigo® for rare brain tumors in the United States, which significantly boosted sales of oncology medications [1] - The cardiovascular metabolism sector showed stable performance, contributing 43.3% to the group's total revenue, with strong sales performance from the core product, the venous disease treatment drug Aimailang® [1]